1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (510) 643-6791
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells
Article first published online: 29 OCT 2003
DOI: 10.1002/cncr.11844
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Zhang, J., Hsu B.A., J. C., Kinseth B.A., M. A., Bjeldanes, L. F. and Firestone, G. L. (2003), Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. Cancer, 98: 2511–2520. doi: 10.1002/cncr.11844
Publication History
- Issue published online: 17 NOV 2003
- Article first published online: 29 OCT 2003
- Manuscript Accepted: 8 SEP 2003
- Manuscript Revised: 13 AUG 2003
- Manuscript Received: 16 JUN 2003
Funded by
- NIH Public Health Service
- National Cancer Institute. Grant Number: CA69056
- California Department of Health Services. Grant Number: 99-00497V-10010
REFERENCES
- 1, , , , , . Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999; 20: 22–45.
- 2, . Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998; 19: 365–396.
- 3, . Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987; 214: 317–322.
- 4. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991; 145: 907–923.
- 5, , , . Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol. 1997; 158: 319–325.
- 6, , , , , . Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med. 1993; 16: 475–492.
- 7, , . Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr Cancer. 1992; 18: 1–29.
- 8, , , . Whole-grain intake and cancer: an expanded review and meta-analysis. Nutr Cancer. 1998; 30: 85–95.
- 9, , , . Diet intervention for modifying cancer risk. Prog Clin Biol Res. 1996; 395: 223–234.
- 10, , . Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol. 1996; 51: 1069–1076.
- 11, , . Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst. 1975; 54: 985–988.
- 12, , , . Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis. 1991; 12: 1571–1574.
- 13, . Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 1978; 38: 1410–1413.
- 14, , . Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res. 1994; 54: 1446–1449.
- 15, . The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part II]. Curr Med Chem. 1998; 5: 469–491.
- 16, . The chemistry and pharmacology of indole-3-carbinol (indole-3-methanol) and 3-(methoxymethyl)indole. [Part I]. Curr Med Chem. 1998; 5: 337–352.
- 17, , , . Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res. 1994; 54: 5848–5855.
- 18, . Antitumour promoting activity of indole-3-carbinol in mouse skin carcinogenesis. Cancer Lett. 1998; 134: 91–95.
- 19, , , et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem. 1998; 273: 3838–3847.
- 20, , , et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res. 1999; 59: 1244–1251.
- 21, , , . Indole-3-carbinole inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 promoter. J Biol Chem. 2001; 276: 22332–22340.
- 22, , . Indole-3-carbinol and 3,3′-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem Toxicol 2003; 41: 745–752.
- 23, , , et al. Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. FEBS Lett. 2003; 544: 246–251.
- 24, , , et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999; 91: 1869–1876.
- 25, . G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology. 2000; 55: 316–322.
- 26. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000; 60: 3689–3695.
- 27. Cancer cell cycles. Science. 1996; 274: 1672–1677.
- 28, , , , . Prognostic value and expression of p21 (waf1/cip1) protein in prostate cancer. Prostate. 1999; 39: 8–15.Direct Link:
- 29, . Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev. 1998; 17: 337–344.
- 30, , , et al. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int. 1998; 61: 90–94.
- 31, , , et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998; 58: 542–548.
- 32, . Transcriptional regulation of the p21 (WAF1/CIP1) gene. Exp Cell Res. 1999; 246: 280–289.
- 33, , , et al. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 1999; 5: 977–983.
- 34, , , et al. Retinoblastoma, a tumor suppressor, is a eoactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem Biophys Res Commun. 1998; 248: 361–367.
- 35, , . Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997; 57: 4511–4516.
- 36, , . Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol. 2000; 14: 753–760.
- 37, , . Development of human prostate cancer models for chemoprevention and experimental therapeutics studies. J Cell Biochem Suppl. 1997; 29: 174–181.Direct Link:
- 38, , , et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res. 1997; 3: 2493–2500.
- 39, , , , . Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17: 16–23.
- 40, , , , . Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978; 21: 274–281.Direct Link:
- 41, , , et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology. 1995; 136: 796–803.
- 42, , , et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995; 6: 1417–1426.
- 43, , . Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000; 7: 211–247.
- 44, . Flutamide: an antiandrogen for advanced prostate cancer. Ann Pharmacother. 1990; 24: 616–623.
- 45, , , , . Abnormal cell cycle regulation in malignancy. Am J Clin Pathol. 1999; 112(1 Suppl 1 ): S40–52.
- 46, , , et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 1997; 57: 1250–1254.
- 47. Facts and future lines of research in prostate cancer: concluding remarks. BJU Int 2000; 85 Suppl 2: 49–51.Direct Link:
- 48, . Prognostic markers in localized prostate cancer: from microscopes to molecules. Cancer Metastasis Rev. 1998; 17: 429–437.
- 49, , , , , . Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys. Clin Endocrinol (Oxf). 1999; 50: 203–210.